Top

Published in:

01-04-2003 | Article selection

Articles selected from Faculty of 1000 in May 2003

Author: Valerie Speirs

Published in: Breast Cancer Research | Issue 2/2003

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: From the Cover: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003, 100: 3983-3988. For the Faculty of 1000 evaluation of this article please see http://breast-cancer-research.com/reports/bcr610.asp#al-hajj CrossRefPubMedPubMedCentral

Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Leahy DJ: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003, 421: 756-60. For the Faculty of 1000 evaluation of this article please see http://breast-cancer-research.com/reports/bcr610.asp#cho CrossRefPubMed

Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, Kluijt I, Dommering C, Verhoef S, Schouten JP, van't Veer LJ, Pals G: Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res. 2003, 63: 1449-1453. For the Faculty of 1000 evaluation of this article please see http://breast-cancer-research.com/reports/bcr610.asp#hogervorst PubMed

Borrell-Pagès M, Rojo F, Albanell J, Baselga J, Arribas J: TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J. 2003, 22: 1114-1124. For the Faculty of 1000 evaluation of this article please see http://breast-cancer-research.com/reports/bcr610.asp#borrell-pages CrossRefPubMedPubMedCentral

Title: Articles selected from Faculty of 1000 in May 2003
Author: Valerie Speirs
Publication date: 01-04-2003
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 2/2003
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr610

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 2/2003

Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer

Breast cancer cell lines: friend or foe?

CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors

Articles selected from Faculty of 1000 in October 2002

A candidate metastasis-associated DNA marker for ductal mammary carcinoma

Articles selected from Faculty of 1000 in March 2003

Keynote webinar | Spotlight on antibody–drug conjugates in cancer